Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
Conditions
Interventions
Amivantamab IV
Amivantamab SC
+12 more
Locations
93
United States
Ironwood Cancer and Research Center
Chandler, Arizona, United States
City of Hope
Duarte, California, United States
Providence Fullerton
Fullerton, California, United States
Los Angeles Cancer Network
Glendale, California, United States
City of Hope Seacliff
Huntington Beach, California, United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States
Start Date
February 16, 2024
Primary Completion Date
May 31, 2027
Completion Date
January 31, 2032
Last Updated
April 13, 2026
NCT06855771
NCT06758401
NCT06667908
NCT04165798
NCT06875310
NCT07046923
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions